{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:31:01Z","timestamp":1789759861498,"version":"4.0.1"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2021,5,21]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Drug Repurposing (DR) is an alternative to the traditional drug discovery process. It is\ncost and time effective,with high returns and low-risk process that can tackle the increasing need\nfor interventions for varied diseases and new outbreaks. Repurposing of old drugs for other diseases\nhas gained wider attention, as there have been several old drugs approved by the FDA for new\ndiseases. In the global emergency of COVID-19 pandemic, this is one of the strategies implemented\nin the repurposing of old anti-infective, anti-rheumatic and anti-thrombotic drugs. The goal of\nthe current review is to elaborate the process of DR, its advantages, repurposed drugs for a plethora\nof disorders, and the evolution of related academic publications. Further, detailed are the computational\napproaches: literature mining and semantic inference, network-based drug repositioning, signature\nmatching, retrospective clinical analysis, molecular docking and experimental phenotypic\nscreening. We discuss the legal and economic potential barriers in DR, existent collaborative models\nand recommendations for overcoming these hurdles and leveraging the complete potential of\nDR in finding new indications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389203721666200921152853","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T05:39:45Z","timestamp":1600753185000},"page":"251-271","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-6268","authenticated-orcid":true,"given":"Talambedu","family":"Usha","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Bangalore University, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-0114","authenticated-orcid":true,"given":"Sushil K.","family":"Middha","sequence":"additional","affiliation":[{"name":"DBT-BIF Centre, Department of Biotechnology, Maharani Lakshmi Ammanni College for Women(mLAC), Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha A.","family":"Kukanur","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, mLAC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachamadugu V.","family":"Shravani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, mLAC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahantesh N.","family":"Anupama","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, mLAC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagasamudram","family":"Harshitha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, mLAC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameena","family":"Rahamath","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, mLAC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"DBT-BIF Centre, Department of Biotechnology, Maharani Lakshmi Ammanni College for Women(mLAC), Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind K.","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Bodoland University, Kokrajhar- 783370, BTAD, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Escott K.J.; Hopper S.; Wells A.; Doig A.; Guilliams T.; Latimer J.; McNamee C.; Norris A.; Sanseau P.; Cavalla D.; Pirmohamed M.; Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"Langedijk J.","year":"2015","unstructured":"Langedijk J.; Mantel-Teeuwisse A.K.; Slijkerman D.S.; Schutjens M.H.; Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015,20(8),1027-1034","journal-title":"Drug Discov Today"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"Kola I.","year":"2004","unstructured":"Kola I.; Landis J.; Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004,3(8),711-715","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","volume":"1871","author":"Nowak-Sliwinska P.","year":"2019","unstructured":"Nowak-Sliwinska P.; Scapozza L.; Ruiz I Altaba A.; Altaba A.; Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019,1871(2),434-454","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0140-6736(72)92581-0","volume":"2","author":"Gasic G.J.","year":"1972","unstructured":"Gasic G.J.; Gasic T.B.; Murphy S.; Anti-metastatic effect of aspirin. Lancet 1972,2(7783),932-933","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1365-2036.2006.02960.x","volume":"24","author":"Kang J.Y.","year":"2006","unstructured":"Kang J.Y.; Elders A.; Majeed A.; Maxwell J.D.; Bardhan K.D.; Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006,24(1),65-79","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clon.2013.03.001","volume":"25","author":"Phillips I.","year":"2013","unstructured":"Phillips I.; Langley R.; Gilbert D.; Ring A.; Aspirin as a treatment for cancer. Clin Oncol (R Coll Radiol) 2013,25(6),333-335","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11912-013-0351-3","volume":"15","author":"Thorat M.A.","year":"2013","unstructured":"Thorat M.A.; Cuzick J.; Role of aspirin in cancer prevention. Curr Oncol Rep 2013,15(6),533-540","journal-title":"Curr Oncol Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archinte.167.6.562","volume":"167","author":"Chan A.T.","year":"2007","unstructured":"Chan A.T.; Manson J.E.; Feskanich D.; Stampfer M.J.; Colditz G.A.; Fuchs C.S.; Long-term aspirin use and mortality in women. Arch Intern Med 2007,167(6),562-572","journal-title":"Arch Intern Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.2014.271","volume":"111","author":"Alfonso L.","year":"2014","unstructured":"Alfonso L.; Ai G.; Spitale R.C.; Bhat G.J.; Molecular targets of aspirin and cancer prevention. Br J Cancer 2014,111(1),61-67","journal-title":"Br J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","volume":"92","author":"Cl\u00e0ria J.","year":"1995","unstructured":"Cl\u00e0ria J.; Serhan C.N.; Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995,92(21),9475-9479","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.seminoncol.2015.09.010","volume":"43","author":"Umar A.","year":"2016","unstructured":"Umar A.; Steele V.E.; Menter D.G.; Hawk E.T.; Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 2016,43(1),65-77","journal-title":"Semin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"233re2","DOI":"10.1126\/scitranslmed.3008481","volume":"6","author":"Fink S.P.","year":"2014","unstructured":"Fink S.P.; Yamauchi M.; Nishihara R.; Jung S.; Kuchiba A.; Wu K.; Cho E.; Giovannucci E.; Fuchs C.S.; Ogino S.; Markowitz S.D.; Chan A.T.; Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014,6(233),233re2","journal-title":"Sci Transl Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1472-8206.2004.00285.x","volume":"18","author":"Umar A.","year":"2004","unstructured":"Umar A.; Boisseau M.; Yusup A.; Upur H.; B\u00e9gaud B.; Moore N.; Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam Clin Pharmacol 2004,18(5),559-563","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.cellsig.2008.02.004","volume":"20","author":"Pan M.R.","year":"2008","unstructured":"Pan M.R.; Chang H.C.; Hung W.C.; Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras\/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 2008,20(6),1134-1141","journal-title":"Cell Signal"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1001\/jama.2013.6599","volume":"309","author":"Nishihara R.","year":"2013","unstructured":"Nishihara R.; Lochhead P.; Kuchiba A.; Jung S.; Yamauchi M.; Liao X.; Imamura Y.; Qian Z.R.; Morikawa T.; Wang M.; Spiegelman D.; Cho E.; Giovannucci E.; Fuchs C.S.; Chan A.T.; Ogino S.; Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013,309(24),2563-2571","journal-title":"JAMA"},{"key":"ref=17","unstructured":"(Accessed April 21, 2020) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02394769"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"Fan H.H.","year":"2020","unstructured":"Fan H.H.; Wang L.Q.; Liu W.L.; An X.P.; Liu Z.D.; He X.Q.; Song L.H.; Tong Y.G.; Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl) 2020,133(9),1051-1056","journal-title":"Chin Med J (Engl)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-020-01590-2","volume":"39","author":"Ciliberto G.","year":"2020","unstructured":"Ciliberto G.; Mancini R.; Paggi M.G.; Drug repurposing against COVID-19: focus on anticancer agents. J Exp Clin Cancer Res 2020,39(1),86","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ddstr.2011.10.003","volume":"8","author":"Muthyala R.","year":"2011","unstructured":"Muthyala R.; Orphan\/rare drug discovery through drug repositioning. Drug Discov Today Ther Strateg 2011,8(3-4),71-76","journal-title":"Drug Discov Today Ther Strateg"},{"key":"ref=21","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01169"},{"key":"ref=22","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00945"},{"key":"ref=23","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00105"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6378137","author":"Lee H.","year":"2016","unstructured":"Lee H.; Kim Y.; Drug Repurposing is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders Schizophr Res Treat 2016","journal-title":"Schizophr Res Treat"},{"key":"ref=25","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01041"},{"key":"ref=26","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00605"},{"key":"ref=27","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00755"},{"key":"ref=28","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00681"},{"key":"ref=29","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB08891"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"(Accessed April 18, 2020) http:\/\/dx.doi.org\/10.1155\/2016\/6378137","DOI":"10.1155\/2016\/6378137"},{"key":"ref=31","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00602"},{"key":"ref=32","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00678"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/DDDT.S46289","volume":"7","author":"Allarakhia M.","year":"2013","unstructured":"Allarakhia M.; Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther 2013,7,753-766","journal-title":"Drug Des Devel Ther"},{"key":"ref=34","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00675"},{"key":"ref=35","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00674"},{"key":"ref=36","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00657"},{"key":"ref=37","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01043"},{"key":"ref=38","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00268"},{"key":"ref=39","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00834"},{"key":"ref=40","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00993"},{"key":"ref=41","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB06788"},{"key":"ref=42","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00637"},{"key":"ref=43","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00290"},{"key":"ref=44","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01590"},{"key":"ref=45","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00602"},{"key":"ref=46","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB06788"},{"key":"ref=47","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB04884"},{"key":"ref=48","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00350"},{"key":"ref=49","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01394"},{"key":"ref=50","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00260"},{"key":"ref=51","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00798"},{"key":"ref=52","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB01611"},{"key":"ref=53","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB09031"},{"key":"ref=54","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00268"},{"key":"ref=55","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00203"},{"key":"ref=56","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00495"},{"key":"ref=57","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/drugs\/DB00476"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","volume":"27","author":"Park K.","year":"2019","unstructured":"Park K.; A review of computational drug repurposing. Transl Clin Pharmacol 2019,27(2),59-63","journal-title":"Transl Clin Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.2174\/1568026618666180101163651","volume":"17","author":"Usha T.","year":"2017","unstructured":"Usha T.; Shanmugarajan D.; Goyal A.K.; Kumar C.S.; Middha S.K.; Recent Updates on Computer-aided Drug Discovery: Time for a Paradigm Shift. Curr Top Med Chem 2017,17(30),3296-3307","journal-title":"Curr Top Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1080\/07391102.2017.1354783","volume":"36","author":"Dhivya S.","year":"2018","unstructured":"Dhivya S.; Suresh Kumar C.; Bommuraj V.; Janarthanam R.; Chandran M.; Usha T.; Middha S.K.; A study of comparative modelling, simulation and molecular dynamics of CXCR3 receptor with lipid bilayer. J Biomol Struct Dyn 2018,36(9),2361-2372","journal-title":"J Biomol Struct Dyn"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s13311-014-0325-7","volume":"12","author":"Kim T-W.","year":"2015","unstructured":"Kim T-W.; Drug repositioning approaches for the discovery of new therapeutics for Alzheimer\u2019s disease. Neurotherapeutics 2015,12(1),132-142","journal-title":"Neurotherapeutics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"654","DOI":"10.7150\/ijbs.9224","volume":"10","author":"Shim J.S.","year":"2014","unstructured":"Shim J.S.; Liu J.O.; Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 2014,10(7),654-663","journal-title":"Int J Biol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-4939-0709-0_14","volume":"1159","author":"Tari L.B.","year":"2014","unstructured":"Tari L.B.; Patel J.H.; Systematic drug repurposing through text mining. Methods Mol Biol 2014,1159,253-267","journal-title":"Methods Mol Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1039\/c3mb25382a","volume":"9","author":"Wu Z.","year":"2013","unstructured":"Wu Z.; Wang Y.; Chen L.; Network-based drug repositioning. Mol Biosyst 2013,9(6),1268-1281","journal-title":"Mol Biosyst"},{"key":"ref=65","unstructured":"(Accessed April 18, 2020) https:\/\/www.biopharmatrend.com\/post\/45-27-web-resources-for- target-hunting-in-drug-discovery\/"},{"key":"ref=66","unstructured":"(Accessed April 18, 2020) https:\/\/www.ncbi.nlm.nih.gov\/gene"},{"key":"ref=67","unstructured":"(Accessed April 18, 2020) http:\/\/geneontology.org\/"},{"key":"ref=68","unstructured":"(Accessed April 18, 2020) https:\/\/www.uniprot.org\/"},{"key":"ref=69","unstructured":"(Accessed April 18, 2020) https:\/\/www.drugbank.ca\/"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1038\/s41598-019-42806-6","volume":"9","author":"Malas T.B.","year":"2019","unstructured":"Malas T.B.; Vlietstra W.J.; Kudrin R.; Starikov S.; Charrout M.; Roos M.; Peters D.J.M.; Kors J.A.; Vos R.; \u2019t Hoen P.A.C.; van Mulligen E.M.; Hettne K.M.; Drug prioritization using the semantic properties of a knowledge graph. Sci Rep 2019,9(1),6281","journal-title":"Sci Rep"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"Xue H.","year":"2018","unstructured":"Xue H.; Li J.; Xie H.; Wang Y.; Review of drug repositioning approaches and resources. Int J Biol Sci 2018,14(10),1232-1244","journal-title":"Int J Biol Sci"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-8955-3_6","author":"Alaimo S.","year":"2019","unstructured":"Alaimo S.; Pulvirenti A.;  Computational Methods for Drug Repurposing 2019,97-113","journal-title":"Computational Methods for Drug Repurposing"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2043-9113-2-1","volume":"2","author":"Yeh S.H.","year":"2012","unstructured":"Yeh S.H.; Yeh H.Y.; Soo V.W.; A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer. J Clin Bioinforma 2012,2(1),1","journal-title":"J Clin Bioinforma"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-5-S1-S11","volume":"5","author":"Li Z.","year":"2011","unstructured":"Li Z.; Wang R.S.; Zhang X.S.; Two-stage flux balance analysis of metabolic networks for drug target identification. BMC Syst Biol 2011,5(Suppl. 1),S11","journal-title":"BMC Syst Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/msb.2011.35","volume":"7","author":"Folger O.","year":"2011","unstructured":"Folger O.; Jerby L.; Frezza C.; Gottlieb E.; Ruppin E.; Shlomi T.; Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011,7,501","journal-title":"Mol Syst Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1109\/TCBB.2014.2325031","volume":"11","author":"Fakhraei S.","year":"2014","unstructured":"Fakhraei S.; Huang B.; Raschid L.; Getoor L.; Network-Based Drug-Target Interaction Prediction with Probabilistic Soft Logic. IEEE\/ACM Trans Comput Biol Bioinformatics 2014,11(5),775-787","journal-title":"IEEE\/ACM Trans Comput Biol Bioinformatics"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"i232","DOI":"10.1093\/bioinformatics\/btn162","volume":"24","author":"Yamanishi Y.","year":"2008","unstructured":"Yamanishi Y.; Araki M.; Gutteridge A.; Honda W.; Kanehisa M.; Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008,24(13),i232-i240","journal-title":"Bioinformatics"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e62975","DOI":"10.1371\/journal.pone.0062975","volume":"8","author":"Chen H.","year":"2013","unstructured":"Chen H.; Zhang Z.; A semi-supervised method for drug-target interaction prediction with consistency in networks. PLoS One 2013,8(5),e62975","journal-title":"PLoS One"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1093\/bioinformatics\/btr500","volume":"27","author":"van Laarhoven T.","year":"2011","unstructured":"van Laarhoven T.; Nabuurs S.B.; Marchiori E.; Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 2011,27(21),3036-3043","journal-title":"Bioinformatics"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1752-0509-4-S2-S6","volume":"4","author":"Xia Z.","year":"2010","unstructured":"Xia Z.; Wu L.Y.; Zhou X.; Wong S.T.; Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst Biol 2010,4(Suppl. 2),S6","journal-title":"BMC Syst Biol"},{"key":"ref=81","first-page":"506","volume":"19","author":"Musa A.","year":"2018","unstructured":"Musa A.; Ghoraie L.S.; Zhang S.D.; Glazko G.; Yli-Harja O.; Dehmer M.; Haibe-Kains B.; Emmert-Streib F.; A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 2018,19(3),506-523","journal-title":"Brief Bioinform"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.2174\/1568026616666160530181149","volume":"16","author":"Luo H.","year":"2016","unstructured":"Luo H.; Mattes W.; Mendrick D.L.; Hong H.; Molecular Docking for Identification of Potential Targets for Drug Repurposing. Curr Top Med Chem 2016,16(30),3636-3645","journal-title":"Curr Top Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13199-016-0417-8","volume":"70","author":"Middha S.K.","year":"2016","unstructured":"Middha S.K.; Lokesh P.; Goyal A.K.; Prashanth H.P.; Bhardwaj A.; \nIn Silico exploration of cyclooxygenase inhibitory activity of natural compounds found in Myrica nagi using LC-MS. Symbiosis 2016,70,169-178","journal-title":"Symbiosis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/B978-0-12-816125-8.00006-7","author":"Kumar S.","year":"2019","unstructured":"Kumar S.; Kumar S.;  In Silico Drug Design 2019,161-189","journal-title":"In Silico Drug Design"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fphar.2017.00298","volume":"8","author":"March-Vila E.","year":"2017","unstructured":"March-Vila E.; Pinzi L.; Sturm N.; Tinivella A.; Engkvist O.; Chen H.; Rastelli G.; On the Integration of In Silico Drug Design Methods for Drug Repurposing. Front Pharmacol 2017,8,298","journal-title":"Front Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4103\/pm.pm_56_19","volume":"15","author":"Prashanth Kumar H.P.","year":"2019","unstructured":"Prashanth Kumar H.P.; Panda P.; Karunakar P.; Shiksha K.; Singh L.; Ramesh N.; Usha T.; Middha S.K.; Potential Cyclooxygenase (COX-2) enzyme inhibitors from Myrica nagi-from in-silico to in-vitro investigation. Pharmacogn Mag 2019,15(64),280-287","journal-title":"Pharmacogn Mag"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","volume":"248","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020,248,117477","journal-title":"Life Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.pt.2019.05.004","volume":"35","author":"Aulner N.","year":"2019","unstructured":"Aulner N.; Danckaert A.; Ihm J.; Shum D.; Shorte S.L.; Next- Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases. Trends Parasitol 2019,35(7),559-570","journal-title":"Trends Parasitol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2013.07.001","volume":"18","author":"Zheng W.","year":"2013","unstructured":"Zheng W.; Thorne N.; McKew J.C.; Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 2013,18(21-22),1067-1073","journal-title":"Drug Discov Today"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1039\/9781849734912-00086","author":"Lipinski C.A.","year":"2012","unstructured":"Lipinski C.A.;  Royal Society of Chemistry 2012,86-93","journal-title":"Royal Society of Chemistry"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2147\/DDDT.S129447","volume":"11","author":"Szabo M.","year":"2017","unstructured":"Szabo M.; Svensson Akusj\u00e4rvi S.; Saxena A.; Liu J.; Chandrasekar G.; Kitambi S.S.; Cell and small animal models for phenotypic drug discovery. Drug Des Devel Ther 2017,11,1957-1967","journal-title":"Drug Des Devel Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cell.2014.03.034","volume":"157","author":"Gilbertson R.J.","year":"2014","unstructured":"Gilbertson R.J.; Driving glioblastoma to drink. Cell 2014,157(2),289-290","journal-title":"Cell"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1242\/dev.143966","volume":"144","author":"Voges H.K.","year":"2017","unstructured":"Voges H.K.; Mills R.J.; Elliott D.A.; Parton R.G.; Porrello E.R.; Hudson J.E.; Development of a human cardiac organoid injury model reveals innate regenerative potential. Development 2017,144(6),1118-1127","journal-title":"Development"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ncb3510","volume":"19","author":"Chen Y.W.","year":"2017","unstructured":"Chen Y.W.; Huang S.X.; de Carvalho A.L.R.T.; Ho S.H.; Islam M.N.; Volpi S.; Notarangelo L.D.; Ciancanelli M.; Casanova J.L.; Bhattacharya J.; Liang A.F.; Palermo L.M.; Porotto M.; Moscona A.; Snoeck H.W.; A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 2017,19(5),542-549","journal-title":"Nat Cell Biol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nprot.2014.020","volume":"9","author":"Takebe T.","year":"2014","unstructured":"Takebe T.; Zhang R.R.; Koike H.; Kimura M.; Yoshizawa E.; Enomura M.; Koike N.; Sekine K.; Taniguchi H.; Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc 2014,9(2),396-409","journal-title":"Nat Protoc"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ncb2894","volume":"16","author":"Takasato M.","year":"2014","unstructured":"Takasato M.; Er P.X.; Becroft M.; Vanslambrouck J.M.; Stanley E.G.; Elefanty A.G.; Little M.H.; Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol 2014,16(1),118-126","journal-title":"Nat Cell Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"Boj S.F.","year":"2015","unstructured":"Boj S.F.; Hwang C.I.; Baker L.A.; Chio I.I.; Engle D.D.; Corbo V.; Jager M.; Ponz-Sarvise M.; Tiriac H.; Spector M.S.; Gracanin A.; Oni T.; Yu K.H.; van Boxtel R.; Huch M.; Rivera K.D.; Wilson J.P.; Feigin M.E.; \u00d6hlund D.; Handly-Santana A.; Ardito-Abraham C.M.; Ludwig M.; Elyada E.; Alagesan B.; Biffi G.; Yordanov G.N.; Delcuze B.; Creighton B.; Wright K.; Park Y.; Morsink F.H.; Molenaar I.Q.; Borel Rinkes I.H.; Cuppen E.; Hao Y.; Jin Y.; Nijman I.J.; Iacobuzio-Donahue C.; Leach S.D.; Pappin D.J.; Hammell M.; Klimstra D.S.; Basturk O.; Hruban R.H.; Offerhaus G.J.; Vries R.G.; Clevers H.; Tuveson D.A.; Organoid models of human and mouse ductal pancreatic cancer. Cell 2015,160(1-2),324-338","journal-title":"Cell"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"Clevers H.","year":"2016","unstructured":"Clevers H.; Modeling Development and Disease with Organoids. Cell 2016,165(7),1586-1597","journal-title":"Cell"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/cb600362d","volume":"2","author":"Chong C.R.","year":"2007","unstructured":"Chong C.R.; Xu J.; Lu J.; Bhat S.; Sullivan D.J.; Liu J.O.; Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007,2(4),263-270","journal-title":"ACS Chem Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"Kim J.","year":"2010","unstructured":"Kim J.; Tang J.Y.; Gong R.; Kim J.; Lee J.J.; Clemons K.V.; Chong C.R.; Chang K.S.; Fereshteh M.; Gardner D.; Reya T.; Liu J.O.; Epstein E.H.; Stevens D.A.; Beachy P.A.; Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010,17(4),388-399","journal-title":"Cancer Cell"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1303818","volume":"22","author":"Tobinick E.L.","year":"2009","unstructured":"Tobinick E.L.; The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009,22(2),119-125","journal-title":"Drug News Perspect"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","volume":"24","author":"Neuberger A.","year":"2019","unstructured":"Neuberger A.; Oraiopoulos N.; Drakeman D.L.; Renovation as innovation: is repurposing the future of drug discovery research? Drug Discov Today 2019,24(1),1-3","journal-title":"Drug Discov Today"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"Talevi A.","year":"2020","unstructured":"Talevi A.; Bellera C.L.; Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 2020,15(4),397-401","journal-title":"Expert Opin Drug Discov"},{"key":"ref=104","unstructured":"(Accessed May 18, 2020) https:\/\/ncats.nih.gov\/index.php"},{"key":"ref=105","unstructured":"(Accessed May 18, 2020) https:\/\/www.excelra.com\/ excelra-maruho-drugrepurposing-collaboration\/"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186156\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T14:11:00Z","timestamp":1640268660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186156\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203721666200921152853","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}